Project Grant HT94252510382
Award Date
6/1/25
Completion Date
5/31/28
Dollars Obligated
$658K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Similar Awards
The federal Project Grant award of $405,341.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports research conducted by the Children's Research Institute in Washington, DC to develop innovative pharmacological approaches for the treatment of Duchenne muscular dystrophy (DMD). The institute will leverage its expertise in areas like genetics, neuroscience, and translational medicine to explore novel therapeutic...
This $563,484.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Duke University to regulate skeletal muscle fibrosis in Duchenne muscular dystrophy. The two-year award, effective June 1, 2024 through May 31, 2026, will enable Duke University's research team to advance understanding and potential treatments for this debilitating neuromuscular disorder affecting military service members and...
This $1,104,029 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will support research at the University of Florida to investigate MRI/MRS markers of skeletal muscle disease progression and vascular function in non-ambulatory individuals with Duchenne muscular dystrophy (DMD). The research will be conducted over a 3-year period from November 1, 2024 to October 31, 2027. The funding will enable the University of...
This $953,125 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program will support research at the University of Florida to investigate MRI/MRS markers of skeletal muscle disease progression and vascular function in nonambulatory individuals with Duchenne muscular dystrophy. The research project will run from November 1, 2024 to October 31, 2027 and aims to advance understanding of neurodegenerative diseases...
This Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $572,306 in funding to the University of Washington for a 3-year research project to develop "ENHANCED GENE THERAPY FOR DMD USING LARGER DYSTROPHINS AND LOWER VECTOR DOSES". The aim is to advance gene therapy approaches for treating Duchenne muscular dystrophy (DMD) by utilizing larger dystrophin gene constructs and reducing the required vector doses. The...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,708,955 project grant to the University of Washington to support a 3-year research study on "Enhanced Gene Therapy for DMD Using Larger Dystrophins and Lower Vector Doses". The grant, which commenced on September 15, 2023 and will be completed by September 14, 2026, aims to advance gene therapy approaches for the treatment of Duchenne muscular dystrophy (DMD). The University...
This $485,597.91 federal Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to support research at the Universite De Sherbrooke in Canada. The award will fund a 3-year project from August 1, 2024 to July 31, 2027 focused on understanding the "CONTRIBUTION OF ALTERNATIVE SPLICING TO NEUROFIBROMAGENESIS." The research aims to advance scientific knowledge in the area of neurological disorders, which...
The federal Project Grant award of $777,659.00 from the Department of the Army Medical Command's Military Medical Research and Development (CFDA 12.420) program supports the Children's Research Institute's work on "USE OF PRORESOLUTION AND RESTORATIVE PHARMACOLOGY APPROACHES FOR DMD THERAPY". The award, with a performance period from August 1, 2025 to July 31, 2028, will fund the institute's research to develop novel therapeutic approaches and medical interventions for Duchenne...
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) program, provides $345,664.00 to support an advanced biomedical research initiative focused on developing an AAV-microdystrophin gene therapy for Duchenne muscular dystrophy. The research aims to enhance the immune protection of the gene therapy through capsid bioengineering. The award was granted on December 1, 2024 with a final completion date of November 30, 2026. The...
The University of British Columbia will receive $622,872 under a Project Grant award from the Department of the Army Medical Command. The grant is part of the Military Medical Research and Development program (CFDA 12.420) and will support research to detect early relapse in patients with early-stage testicular germ cell tumors using circulating miR371a-3p biomarkers. The research will be conducted between September 2022 and September 2025 at the University's facilities in Ottawa, Canada. The...